Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y
03:54pm, Monday, 10'th Aug 2020
Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
12:00am, Friday, 07'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Editas Medicine Announces Second Quarter 2020 Results and Update
08:05pm, Thursday, 06'th Aug 2020
Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020Plan to file IND for EDIT-301 for sickle
Editas Medicine Regains Full Global Rights to Ocular Medicines
08:01pm, Thursday, 06'th Aug 2020
Enhances strategic flexibility and control of lead programs, including EDIT-101CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing compan
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
12:00am, Thursday, 06'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
Editas Medicine (EDIT) to Release Earnings on Thursday
06:40am, Wednesday, 05'th Aug 2020
Editas Medicine (NASDAQ:EDIT) will issue its quarterly earnings data after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.80) per share for the quar
Global CRISPR Technology Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com
12:00am, Tuesday, 04'th Aug 2020
The
Editas Medicine Inc (NASDAQ:EDIT) Shares Sold by Creative Planning
06:48am, Sunday, 02'nd Aug 2020
Creative Planning decreased its stake in Editas Medicine Inc (NASDAQ:EDIT) by 59.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Comm
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to Decline
04:33pm, Thursday, 30'th Jul 2020
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
12:00pm, Wednesday, 29'th Jul 2020
CAMBRIDGE, Mass. and SOMERSET, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced del
Editas Medicine Appoints Gad Berdugo as Chief Business Officer
08:01pm, Monday, 27'th Jul 2020
Gad Berdugo Gad Berdugo, Chief Business Officer, Editas MedicineCAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announ
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now | The Motley Fool
12:10pm, Sunday, 26'th Jul 2020
A simple investment in CRISPR Therapeutics during its IPO four years ago would have netted investors nearly six times their investment today.
